Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: Potential implications for the metabolism of HIV drugs

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Drug metabolism via the cytochrome P450 (CYP450) system has emerged as an important determinant in the occurrence of several drug interactions (adverse drug reactions, reduced pharmacological effect, drug toxicities). In particular, CYP3A4 and CYP3A5 (interacting with more than 60% of licensed drugs) exhibit the most individual variations of gene expression, mostly caused by single nucleotide polymorphisms (SNPs) within the regulatory region of the CYP3A4 and CYP3A5 genes which might affect the level of enzyme production.In this study, we sought to improve the performance of sensitive screening for CYP3A polymorphism detection in twenty HIV-1 infected patients undergoing lopinavir/ritonavir (LPV/r) monotherapy.Methods: The study was performed by an effective, easy and inexpensive home-made Polymerase Chain Reaction Direct Sequencing approach for analyzing CYP3A4 and CYP3A5 genes which can detect both reported and unreported genetic variants potentially associated with altered or decreased functions of CYP3A4 and CYP3A5 proteins. Proportions and tests of association were used.Results: Among the genetic variants considered, CYP3A4*1B (expression of altered function) was only found in 3 patients (15%) and CYP3A5*3 (expression of splicing defect) in 3 other patients (15%). CYP3A5*3 did not appear to be associated with decreased efficacy of LPV/r in any patient, since none of the patients carrying this variant showed virological rebound during LPV/r treatment or low levels of TDM. In contrast, low-level virological rebound was observed in one patient and a low TDM level was found in another; both were carrying CYP3A4*1B.Conclusions: Our method exhibited an overall efficiency of 100% (DNA amplification and sequencing in our group of patients). This may contribute to producing innovative results for better understanding the inter-genotypic variability in gene coding for CYP3A, and investigating SNPs as biological markers of individual response to drugs requiring metabolism via the cytochrome P450 system.

Original languageEnglish
Article number76
JournalBMC Medical Genetics
Volume15
Issue number1
DOIs
Publication statusPublished - Jul 2 2014

Fingerprint

Cytochrome P-450 CYP3A
Single Nucleotide Polymorphism
HIV
Pharmaceutical Preparations
Genes
Lopinavir
Ritonavir
Drug-Related Side Effects and Adverse Reactions
Cytochrome P-450 Enzyme System
Nucleic Acid Regulatory Sequences
DNA Sequence Analysis
Drug Interactions

Keywords

  • Cytocrome P450
  • Pharmacogenetics
  • Polymorphisms
  • Variability

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

@article{5c547fcedc714074905e935ef0bd326d,
title = "Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: Potential implications for the metabolism of HIV drugs",
abstract = "Background: Drug metabolism via the cytochrome P450 (CYP450) system has emerged as an important determinant in the occurrence of several drug interactions (adverse drug reactions, reduced pharmacological effect, drug toxicities). In particular, CYP3A4 and CYP3A5 (interacting with more than 60{\%} of licensed drugs) exhibit the most individual variations of gene expression, mostly caused by single nucleotide polymorphisms (SNPs) within the regulatory region of the CYP3A4 and CYP3A5 genes which might affect the level of enzyme production.In this study, we sought to improve the performance of sensitive screening for CYP3A polymorphism detection in twenty HIV-1 infected patients undergoing lopinavir/ritonavir (LPV/r) monotherapy.Methods: The study was performed by an effective, easy and inexpensive home-made Polymerase Chain Reaction Direct Sequencing approach for analyzing CYP3A4 and CYP3A5 genes which can detect both reported and unreported genetic variants potentially associated with altered or decreased functions of CYP3A4 and CYP3A5 proteins. Proportions and tests of association were used.Results: Among the genetic variants considered, CYP3A4*1B (expression of altered function) was only found in 3 patients (15{\%}) and CYP3A5*3 (expression of splicing defect) in 3 other patients (15{\%}). CYP3A5*3 did not appear to be associated with decreased efficacy of LPV/r in any patient, since none of the patients carrying this variant showed virological rebound during LPV/r treatment or low levels of TDM. In contrast, low-level virological rebound was observed in one patient and a low TDM level was found in another; both were carrying CYP3A4*1B.Conclusions: Our method exhibited an overall efficiency of 100{\%} (DNA amplification and sequencing in our group of patients). This may contribute to producing innovative results for better understanding the inter-genotypic variability in gene coding for CYP3A, and investigating SNPs as biological markers of individual response to drugs requiring metabolism via the cytochrome P450 system.",
keywords = "Cytocrome P450, Pharmacogenetics, Polymorphisms, Variability",
author = "Giulia Berno and Mauro Zaccarelli and Caterina Gori and Massimo Tempestilli and Andrea Antinori and Perno, {Carlo F.} and Pucillo, {Leopoldo P.} and Roberta D'Arrigo",
year = "2014",
month = "7",
day = "2",
doi = "10.1186/1471-2350-15-76",
language = "English",
volume = "15",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes

T2 - Potential implications for the metabolism of HIV drugs

AU - Berno, Giulia

AU - Zaccarelli, Mauro

AU - Gori, Caterina

AU - Tempestilli, Massimo

AU - Antinori, Andrea

AU - Perno, Carlo F.

AU - Pucillo, Leopoldo P.

AU - D'Arrigo, Roberta

PY - 2014/7/2

Y1 - 2014/7/2

N2 - Background: Drug metabolism via the cytochrome P450 (CYP450) system has emerged as an important determinant in the occurrence of several drug interactions (adverse drug reactions, reduced pharmacological effect, drug toxicities). In particular, CYP3A4 and CYP3A5 (interacting with more than 60% of licensed drugs) exhibit the most individual variations of gene expression, mostly caused by single nucleotide polymorphisms (SNPs) within the regulatory region of the CYP3A4 and CYP3A5 genes which might affect the level of enzyme production.In this study, we sought to improve the performance of sensitive screening for CYP3A polymorphism detection in twenty HIV-1 infected patients undergoing lopinavir/ritonavir (LPV/r) monotherapy.Methods: The study was performed by an effective, easy and inexpensive home-made Polymerase Chain Reaction Direct Sequencing approach for analyzing CYP3A4 and CYP3A5 genes which can detect both reported and unreported genetic variants potentially associated with altered or decreased functions of CYP3A4 and CYP3A5 proteins. Proportions and tests of association were used.Results: Among the genetic variants considered, CYP3A4*1B (expression of altered function) was only found in 3 patients (15%) and CYP3A5*3 (expression of splicing defect) in 3 other patients (15%). CYP3A5*3 did not appear to be associated with decreased efficacy of LPV/r in any patient, since none of the patients carrying this variant showed virological rebound during LPV/r treatment or low levels of TDM. In contrast, low-level virological rebound was observed in one patient and a low TDM level was found in another; both were carrying CYP3A4*1B.Conclusions: Our method exhibited an overall efficiency of 100% (DNA amplification and sequencing in our group of patients). This may contribute to producing innovative results for better understanding the inter-genotypic variability in gene coding for CYP3A, and investigating SNPs as biological markers of individual response to drugs requiring metabolism via the cytochrome P450 system.

AB - Background: Drug metabolism via the cytochrome P450 (CYP450) system has emerged as an important determinant in the occurrence of several drug interactions (adverse drug reactions, reduced pharmacological effect, drug toxicities). In particular, CYP3A4 and CYP3A5 (interacting with more than 60% of licensed drugs) exhibit the most individual variations of gene expression, mostly caused by single nucleotide polymorphisms (SNPs) within the regulatory region of the CYP3A4 and CYP3A5 genes which might affect the level of enzyme production.In this study, we sought to improve the performance of sensitive screening for CYP3A polymorphism detection in twenty HIV-1 infected patients undergoing lopinavir/ritonavir (LPV/r) monotherapy.Methods: The study was performed by an effective, easy and inexpensive home-made Polymerase Chain Reaction Direct Sequencing approach for analyzing CYP3A4 and CYP3A5 genes which can detect both reported and unreported genetic variants potentially associated with altered or decreased functions of CYP3A4 and CYP3A5 proteins. Proportions and tests of association were used.Results: Among the genetic variants considered, CYP3A4*1B (expression of altered function) was only found in 3 patients (15%) and CYP3A5*3 (expression of splicing defect) in 3 other patients (15%). CYP3A5*3 did not appear to be associated with decreased efficacy of LPV/r in any patient, since none of the patients carrying this variant showed virological rebound during LPV/r treatment or low levels of TDM. In contrast, low-level virological rebound was observed in one patient and a low TDM level was found in another; both were carrying CYP3A4*1B.Conclusions: Our method exhibited an overall efficiency of 100% (DNA amplification and sequencing in our group of patients). This may contribute to producing innovative results for better understanding the inter-genotypic variability in gene coding for CYP3A, and investigating SNPs as biological markers of individual response to drugs requiring metabolism via the cytochrome P450 system.

KW - Cytocrome P450

KW - Pharmacogenetics

KW - Polymorphisms

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=84903413505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903413505&partnerID=8YFLogxK

U2 - 10.1186/1471-2350-15-76

DO - 10.1186/1471-2350-15-76

M3 - Article

C2 - 24986243

AN - SCOPUS:84903413505

VL - 15

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

IS - 1

M1 - 76

ER -